Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes

What happened: Zealand Pharma (CPSE:ZEAL) reported positive topline Phase 2 ZUPREME-2 data for petrelintide, an amylin analog, in adults with overweight or obesity and type 2 diabetes. Key numbers: Zealand Pharma is a DKK16.1b biotech group. The content cites a DKK416 fair value. Why it matters: Management said the findings support moving petrelintide into Phase 3 for chronic weight management. The data addresses concern that the pipeline is light on near-term evidence against rivals Novo Nordisk and Eli Lilly. Market: -1.2% by next close ($233.90 on Oct 12), -49.9% YTD

Zealand Pharma (CPSE:ZEAL) reported positive topline Phase 2 ZUPREME-2 data for petrelintide, an amylin analog, in adults with overweight or obesity and type 2 diabetes.

Management said the findings support moving petrelintide into Phase 3 for chronic weight management. The data addresses concern that the pipeline is light on near-term evidence against rivals Novo Nordisk and Eli Lilly. Market: -1.2% by next close ($233.90 on Oct 12), -49.9% YTD